Rapamycin was originally developed as an immunosuppressant drug for organ transplant patients. More recently, it has found a new lease on life as a potential antiaging drug. Rapamycin has not yet been approved for that use in humans, but many gerontologists see it – or similar drugs – as the best hope we have for pharmacologically slowing down the aging process.
A recent study published in the medical journal Aging details what we know and what we do not know about rapamycin and longevity.
Key Takeaways From This Study:
- The evidence that rapamycin can function as an antiaging drug is the product of thousands of scientists working independently all over the world.
- The potential antiaging benefits of rapamycin and similar drugs certainly outweigh its perceived or actual potential risks.
- Rapamycin and similar drugs have been found in clinical trials to extend the lifespan of mice by three times.
- Every indication is that the astounding life-extending results found in animal models with rapamycin will translate to humans.
- Rapamycin and its analog, everolimus, are FDA approved for human use and have been used safely for decades.
You can read the complete study entitled, Rapamycin for longevity: opinion article by clicking on the link.
